TC
CKPT

Tatro Capital’s Checkpoint Therapeutics CKPT Stock Holding History

Tatro Capital’s Portfolio CKPT Stock Details CKPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$33K Hold
1,882
– – 0.02% 84
2021
Q4 		$59K Buy
1,882
+46
+3% +$1.52K 0.04% 93
2021
Q3 		$61K Hold
1,836
– – 0.05% 84
2021
Q2 		$54K Hold
1,836
– – 0.04% 105
2021
Q1 		$58K Hold
1,836
– – 0.04% 100
2020
Q4 		$49K Buy
+1,836
New +$46.5K 0.05% 78

Other funds holding CKPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return
JSMC
Jess S. Morgan & Co Los Angeles, California $115M AUM 16.65% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Tatro Capital's CKPT Position: Q1 2022 in Review

Tatro Capital held its Checkpoint Therapeutics (CKPT) position steady in Q1 2022 at 1,882 shares worth $33K. The position accounts for 0.02% of the portfolio, ranked #84.

Tatro Capital first reported a position in CKPT in Q4 2020 and has held it in 6 quarters since. The position peaked at $61K in Q3 2021. 67 funds tracked by Wall St. Rank hold CKPT as of Q1 2022.

  • Tatro Capital held 1,882 shares of Checkpoint Therapeutics worth $33K as of Q1 2022.
  • Tatro Capital left its Checkpoint Therapeutics share count unchanged in Q1 2022.
  • Checkpoint Therapeutics made up 0.02% of Tatro Capital's portfolio in Q1 2022, its #84 holding.
  • Tatro Capital first reported a position in Checkpoint Therapeutics in Q4 2020 and has held it in 6 quarters since.
  • Tatro Capital's Checkpoint Therapeutics position peaked at $61K in Q3 2021.
  • 67 funds tracked by Wall St. Rank held Checkpoint Therapeutics as of Q1 2022.

Based on Tatro Capital's 13F filing for Q1 2022, filed 13 May 2022.